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S
tandard “Alzheimerology” 
lore holds that the insolubility 
of amyloid plaques and 
neuroﬁ  brillary tangles was a great 
impediment to elucidating the 
molecular composition of each of these 
structures. Roughly 77 years passed 
between Alois Alzheimer’s description 
of the clinical and pathological features 
of the illness suffered by Auguste D. 
and the now classical reports from 
George Glenner, Colin Masters, and 
Konrad Beyreuther describing partial 
solubilization, Edman degradation, 
and primary amino acid sequencing 
of the Aβ peptide (the protein that 
accumulates into amyloid plaques) 
[1–3]. Peter Davies (who discovered 
the cholinergic deﬁ  ciency in Alzheimer 
disease during that same interval [4]) 
has long joked that one easy way to 
purify plaques and tangles is to allow 
the brain from an affected person to 
autolyze and liquefy completely (“on 
a summer sidewalk,” according to one 
colorful variation), whereupon the 
macro structure of the organ would 
disintegrate, leaving behind only 
ﬁ  brous clumps and twists. 
There is little wonder, then, that 
the strategy of treating Alzheimer 
disease with “plaque busting” drugs 
was relatively slowly embraced: 20 
years passed between the availability 
of amyloid aggregation assays and 
the clinical trials of the ﬁ  rst speciﬁ  c 
antiamyloid-aggregation compounds. 
(“Aggregation” is essentially equivalent 
to clumping, and amyloid clumping 
can be monitored in a test tube since 
ﬂ  oating clumps cause light to disperse 
in a measurable fashion). Conventional 
wisdom was nihilistic, holding that 
therapeutic dissolution of amyloid 
deposits was probably too slow to be 
approachable. People love to see a 
dogma challenged, and the availability 
of mouse models of Alzheimer disease 
enabled Brad Hyman’s group to 
show, in 2001, that deposits of human 
Aβ in the transgenic mouse brain 
were surprisingly dynamic, forming 
and, unexpectedly, dissolving over 
a timescale of days [5]. These data 
injected new optimism into the pursuit 
of antiamyloid strategies, and by 
2005, over 30 discrete compounds or 
combinations were in development [6]. 
Old Worries Resurface
Now, with publication of a study by 
David Borchelt’s group in this issue of 
PLoS Medicine [7], old worries about the 
efﬁ  ciency of plaque clearance resurface. 
David Borchelt, Joanna Jankowsky, and 
their colleagues report the development 
of Aβ plaque-forming transgenic mice 
in which pathology is driven by brain-
speciﬁ  c overexpression of a mutated 
form of the human amyloid precursor 
protein (APP). The innovation here 
is that human APP expression due 
to a genetic trick is extinguishable by 
adding the antibiotic tetracycline to 
the mouse food (“tet-off” APP mice). 
As rightly contended by these authors, 
the ability to abolish human APP gene 
expression—instantly and completely—
can be conceptually envisioned 
as equivalent to the most effective 
antiamyloid strategy imaginable: in 
other words, a best-case scenario from 
the point of view of drug efﬁ  cacy. 
The rationale was to see how long 
human amyloid deposits would 
persist in a plaque-laden mouse brain 
once new accretion ceased (i.e., 
once tetracycline switched off new 
mutated human APP production). 
The results are arguably applicable to 
every antiamyloid strategy delivered 
to patients impaired by Alzheimer 
disease, since all are believed to enter 
therapy with at least some existing 
brain plaque burden. In this tet-off 
paradigm, unlike the paradigm used 
earlier by Hyman and colleagues, 
amyloid pathology was allowed to 
accumulate, and then human APP 
expression was completely shut off. 
Borchelt and colleagues were unable 
to detect any change in brain amyloid 
load for at least six months after 
complete cessation of Aβ biogenesis. 
The Borchelt data dovetail well with 
recent biophysical data, proving 
that the thermodynamic barrier to 
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Figure 1. A Large Energy Barrier Prevents 
Rapid Redissolution of Fibrillar Amyloid 
In this issue of PLoS Medicine, Borchelt and 
colleagues demonstrate in the living amyloid-
laden mouse brain that Aβ plaques are 
cleared very slowly, even if synthesis of new 
Aβ precursor molecules is extinguished using 
a tet-off system [7]. In the recent, relevant, 
but independent, X-ray crystallography study 
[8], Nelson et al. envisioned the free-energy 
plot shown above as a graphic description 
of the kinetics of transition from monomeric 
Aβ to ﬁ  brillar Aβ(∆Gformation). For the reverse 
reaction, Nelson et al. envision the ∆Gdissolution as 
the large free-energy barrier to spontaneous 
solubilization of amyloid ﬁ  brils. Presumably, 
it is this ∆Gdissolution that underlies the slow 
disappearance of brain plaques in the Borchelt 
study in transgenic mice. 
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redissolution of amyloid ﬁ  brils is very 
high indeed (Figure 1) [8].
Implications for Therapy 
and Prevention
If this mouse model represents the 
best-case scenario, what are the realistic 
hopes of success for anti-Aβ therapies 
in the treatment of human Alzheimer 
disease? Several points come to 
mind. First, the recent proposal that 
oligomeric/dodecameric forms of Aβ 
(also known as Aβ-derived diffusible 
ligands [ADDLs]) are the real culprits 
in mediating Aβ neurotoxicity [9] 
provides some hope that ADDLs, 
not Aβ plaques, represent the most 
important Aβ biophysical form that 
must be purged in order to cause a 
therapeutic beneﬁ  t. Borchelt and 
colleagues have not yet determined 
what happens to ADDL levels in the 
brains of their tet-off APP mice, but 
such data are eagerly anticipated. 
Second, Borchelt and colleagues’ 
data are consistent with the evidence 
that all model antiamyloid strategies 
are superior when initiated long before 
onset of amyloidosis. Such evidence 
fuels a new initiative of the United 
States Alzheimer’s Association aimed 
not at treating but at preventing 
Alzheimer disease (http://www.alz.
org/maintainyourbrain). Interventional 
strategies early in life should not 
only prevent amyloid pathology, but 
also take advantage of the greater 
regenerative capacity of the human 
brain at younger ages. The wisdom of 
preventing Alzheimer disease is further 
galvanized by the appreciation over the 
last ﬁ  ve years of evidence that many 
modiﬁ  able diet and lifestyle factors 
(body mass index, cholesterol levels, 
control of diabetes and blood pressure, 
and mental and physical exercise) may 
modulate risk for late-life degenerative 
dementia [10]. 
The Challenges Ahead
Signiﬁ  cant challenges lie ahead in 
understanding how these risks and 
pathologies are intertwined, but the 
aging of the baby boom population 
promises an unprecedented epidemic 
of dementia if effective interventions 
are not discovered soon. In the US, the 
population of individuals age 65 years 
and over is the fastest growing segment 
in society, and one-half of individuals 
over 85 experience dementia [11]. On 
a practical level, this means that almost 
everyone will be either a patient or a 
caregiver in the near future. Disasters 
such as tsunamis and hurricanes—as 
painful, dramatic, and expensive as 
they are—pale in comparison to the 
cataclysm our aging societies will face 
if current trends in the epidemiology 
of this dementing illness continue on 
unchecked.  
Acknowledgments
This work was supported by United States 
National Institutes of Health grants NS41017 
(to SG) and NS046006 (to FLH).
References
1. Alzheimer A, Stelzmann RA, Schnitzlein HN, 
Murtagh FR (1995) An English translation 
of Alzheimer’s 1907 paper, “Uber eine 
eigenartige Erkankung der Hirnrinde.” Clin 
Anat 8: 429–431. 
2. Glenner GG, Wong CW (1984) Alzheimer’s 
disease: Initial report of the puriﬁ  cation and 
characterization of a novel cerebrovascular 
amyloid protein. Biochem Biophys Res 
Commun 120: 885–890. 
3. Masters CL, Simms G, Weinman NA, Multhaup 
G, McDonald BL, et al. (1985) Amyloid plaque 
core protein in Alzheimer disease and Down 
syndrome. Proc Natl Acad Sci U S A 82: 
4245–4249. 
4. Davies P (1979) Biochemical changes in 
Alzheimer’s disease-senile dementia: 
Neurotransmitters in senile dementia of the 
Alzheimer’s type. Res Publ Assoc Res Nerv 
Ment Dis 57: 153–166. 
5. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, 
Games D, et al. (2001) Imaging of amyloid-
beta deposits in brains of living mice permits 
direct observation of clearance of plaques with 
immunotherapy. Nat Med 7: 369–372. 
6. Kwon MO, Fischer F, Matthisson M, Herrling 
P (2004) List of drugs in development 
for neurodegenerative diseases. 
Neurodegenerative Dis 1: 113–152. 
7. Jankowsky JL, Slunt HH, Gonzales V, Savonenko 
AV, Wen J, et al. (2005) Persistent amyloidosis 
following suppression of Aβ production in 
a transgenic model of Alzheimer disease. 
PLoS Med 2: e355. DOI: 10.1371/journal.
pmed.0020355
8. Nelson R, Sawaya MR, Balbirnie M, Madsen AØ, 
Riekel C, et al. (2005) Structure of the cross-
beta spine of amyloid-like ﬁ  brils. Nature 435: 
773–778.
9. De Felice FG, Vieira MN, Saraiva LM, 
Figueroa-Villar JD, Garcia-Abreu J, et al. 
(2004) Targeting the neurotoxic species 
in Alzheimer’s disease: Inhibitors of Abeta 
oligomerization. FASEB J 18: 1366–1372. 
10. Marx J (2005) Neuroscience. Preventing 
Alzheimer’s: A lifelong commitment? Science 
309: 864–866. 
11. Hebert LE, Scherr PA, Beckett LA, Albert 
MS, Pilgrim DM, et al. (1995) Age-speciﬁ  c 
incidence of Alzheimer’s disease in a 
community population. JAMA 273: 1354–1359. 
December 2005  |  Volume 2  |  Issue 12  |  e417